This is a preliminary programme. More details and updates will follow in the coming months.

DAY 1 - Friday 4 December 2026

changes may occur

09:00-10:00 | Industry-sponsored satellite symposium
10:00-10:30 | Break
10:30-10:45 | Official opening

Addy van de Luijtgaarden & André Vis

10:45-11:15 | PCa screening and diagnosis in 2026

Moderation: TBD

  • PCa screening in 2026 - Roderick van den Bergh
  • PCa diagnosis in 2026 - Emanuele Messina
  • Discussion and Q&A - All
11:15-12:00 | Hormonal recovery & rehabilitation

Moderation: TBD

  • What do patients need? - Kees Vos
  • TRT: Is it still a taboo in PCa? - Bertrand Tombal
  • Rehabilitation strategies after PCa treatment - Erik van Muilekom
  • Discussion and Q&A - All
12:00-12:30 | Update lecture: Surgery

Moderation: Eva Compérat & Roderick van den Bergh

12:30-13:00 | Update lecture: Individualising mHSPC management: Fine-tuning patient care

Moderation: Gunhild von Amsberg

  • Lecture - Amit Bahl
  • Case discussion and Q&A - Amit Bahl, Alice Bernard-Tessier, Gunhild von Amsberg
13:00-14:00 | Lunch
14:00-15:30 | Case discussion session: High-risk localised and locally advanced prostate cancer

Moderation: TBD

Panel: Vérane Achard, Géraldine Pignot, Bertrand Tombal, Roderick van den Bergh, Jochem van der Voort van Zyp, André Vis

  • Case presentation - Constance Huck, Giovanna Pecoraro, Henning Plage
  • Redefining risk & the impact of PSMA PET imaging
  • Role of ARPI addition to ADT + RT: A reality check
  • RT intensification strategies - Vérane Achard
  • Discussion and Q&A - All
15:30-16:00 | Road to Amsterdam cases

Moderation: TBC

  • Focal salvage therapy in radiorecurrent PCa : Lessons from Utrecht - Jochem van der Voort van Zyp
  • Perioperative treatment intensification in a high-risk population
     
16:00-16:30 | Break
16:30-18:00 | Case discussion session: mHSPC

Moderation: Alice Bernard-Tessier & Rob Jones

Panel: Maria De Santis, Aurelius Omlin, Bertrand Tombal, Addy van de Luijtgaarden, Roderick van den Bergh, Jochem van der Voort van Zyp, André Vis, Gunhild von Amsberg, Thomas Zilli

  • Case presentation - Constance Huck, Giovanna Pecoraro, Henning Plage 
  • From burden to biology: Evolving systemic therapy in mHSPC - Bertrand Tombal 
  • Local control in mHSPC: Defining the role of prostate RT - Jochem van der Voort van Zyp
  • Should everybody receive an ARPI? - André Vis 
  • MDT in mHSPC: Where does the evidence lead us? - Thomas Zilli
  • Discussion and Q&A - All

DAY 2 - Saturday 5 December 2026

changes may occur

08:30-09:30 | Industry-sponsored satellite symposium
09:30-10:00 | Break
10:00-11:00 | APCCC 2026 highlights

Moderation: Aurelius Omlin

  • Introduction - Aurelius Omlin
  • Discussion on APCCC 2026 statements - Panel: André Vis, Gunhild von Amsberg
11:00-11:30 | Update lecture: Post-ARPI mCRPC: Biology, biomarkers and management

Moderation: Gunhild von Amsberg 

  • Lecture - Alice Bernard-Tessier 
  • Case discussion and Q&A - Alice Bernard-Tessier & Gunhild von Amsberg
     
11:30-13:00 | Case discussion session: CRPC

Moderation: Addy van de Luijtgaarden 

Panel: Alice Bernard-Tessier, Rob Jones, Aurelius Omlin, Addy van de Luijtgaarden, Gunhild von Amsberg

  • Case presentation - Constance Huck, Giovanna Pecoraro, Henning Plage
  • mCRPC update: What's new and what's coming?
  • Sequencing decisions: mCRPC dilemma's - Gunhild von Amsberg
  • ARPI alone or PARPi on top? - Aurelius Omlin
13:00-14:00 | Lunch
14:00-14:30 | Update lecture: Radioligand therapy in clinical practice

Moderation: TBD

  • Lecture - Karolien Goffin
  • Discussion and Q&A
     
14:30-15:50 | ESO observatory
  • Welcome and introduction
  • The patient's perspective
  • The pathologist's perspective
  • Debate: Imaging for staging outlook
  • The urologist's perspective on surgery
  • The radiation oncologist's perspective
  • The medical oncologist's perspective
  • Panel discussion on the hottest topics in prostate cancer in 2027
15:50-16:00 | Closing remarks

Bertrand Tombal & Roderick van den Bergh

16:00-16:30 | Farewell drink supported by ESO